Physician-Guided Sleep Support for Aging Populations
The CMS Substance Access BEI creates a new pathway for participating organizations to evaluate eligible hemp products under physician oversight.
TruCBN™ brings the strongest combination of clinical evidence, safety data, and quality infrastructure in the cannabinoid sleep category for BEI evaluation.
If you are a provider or an ACO, this is what you need to know
TruCBN™ is the only hemp-derived sleep ingredient positioned for the BEI program with all of the following:
A completed, peer-reviewed, double-blind, placebo-controlled trial of 1,020 participants.
The 50 mg dose delivered statistically significant improvement in sleep quality versus placebo. All doses outperformed placebo. The 50 mg dose showed the strongest performance when benchmarked against melatonin.
Download the study
A 29-day real-world observational study (n=164)
The study showed that sleep duration increased 38 minutes per night, next-day refreshment improved from 19.95% to 69.61%, and night wakings down from 88.35% to 73.37%. All results statistically significant (p < .05).
Download the study
Comprehensive safety package
Includes 90-day oral toxicity testing, no observed adverse effect level at the highest dose tested, a full genotoxicity package, and supportive human tolerability data from a randomized, placebo-controlled TruCBN™ study.
GMP, ISO 9001, and NSF certifications.
TruCBN™ is a standardized CBN ingredient supported by a comprehensive CMC package, with defined identity, purity, and quality specifications.
Certificate of Analysis on every batch covering potency, pesticides, heavy metals, residual solvents, and microbials.
No other cannabinoid sleep ingredient on the market brings together this level of clinical evidence, safety coverage, and standardization.
A hidden cost category
Poor sleep in older adults is a hidden cost category, closely tied to the downstream events that pressure ACO performance: emergency visits, hospitalizations, medication burden, and slower recovery.
Conventional treatments often make it worse. In older adults, benzodiazepines and sedating approaches increase fall risk, confusion, and care complexity, turning a sleep complaint into exactly the kind of avoidable utilization that erodes shared savings.
Better sleep. Fewer falls. Less downstream cost.
Viewed through that lens, the BEI program’s $500 annual per-beneficiary cap is modest. The real economic question is whether a physician-supervised sleep intervention can offset the much larger downstream costs.
The data points in that direction:
That is the cost-of-care opportunity TruCBN™ is designed to address.
The window is open now
TruCBN™ helps your team prepare early and implement with confidence.
How to get started
1. Request a briefing.
2. We walk your team through the clinical evidence, safety data, and program mechanics.
3. Build your Implementation Plan.
FloraWorks provides technical documentation and compliance support.
Through our partner platform, we support clinical consultation, dosing oversight, adverse event tracking, and real-world evidence collection.
Build your Implementation Plan
Ready to build your Implementation Plan? Tell us about your organization and we will take it from there.